Common BP drug may raise risk of Lung Cancer: Study

It was a nested case-control study using data from 4 Danish national health and administrative registries. Researchers evaluated the new users of ACEIs or angiotensin II receptor blockers in Denmark from January 1, 2000, and followed them until December 31, 2015, for incident lung cancer, death, or emigration. They matched each lung cancer case with up to 20 controls on age, sex, duration of follow-up, and year of cohort entry using risk-set sampling. They used conditional logistic regression to estimate the odds ratios (ORs) for the incident, histologically verified lung cancer with high use of ACEIs which was defined as a cumulative dose above 3650 defined daily doses. They examined different cumulative doses of ACEI (≤1800, 1801–3650, >3650 defined daily doses), and its varied association with lung cancer histology, then they repeated the analyses using thiazides as an active comparator.

Key findings of the study:

• Researchers included a total of 9652 lung cancer cases which was matched to 190 55 controls.

• Upon analysis, they found that the high use of ACEIs was associated with lung cancer (adjusted OR, 1.33).

• They also found that lower cumulative doses have neutral associations (≤1800 defined daily doses OR, 1.01; 1801–3650 defined daily doses OR, 1.03).

• As the Confidence Intervals were wide they included the null when stratifying on histology.

• They found similar results with thiazides (OR, 1.34).

The authors concluded, "Use of high cumulative ACEI doses was associated with modestly increased odds of lung cancer although use of lower doses showed neutral associations. The established benefits of ACEIs should be considered when interpreting these findings".

For further information:

https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.120.006687